Skip to content

This Site is Intended for Healthcare Professionals Only

Search AI Powered
Human content, AI powered search.

Latest Stories

Boots branch closes temporarily as 'no pharmacist available'

Pb Staff writer
By Pb Staff writerMay 09, 2022
Pb Staff writer
See Full Bio

A Boots UK branch store in Hinckley town centre closed 'until further notice' as there was 'no pharmacist available' to work on Monday (May 9).

A local news report said: "The sign on the door reads: "Unfortunately, we are unable to open until further notice. We are working hard to get this rectified.

"We apologies for the inconvenience. Hearing care appointments please wait here to be greeted.""

LeicestershireLive reported a patient saying that their appointment for a hearing aid check had been postponed until Tuesday.

It added: "The customer was surprised to be told by staff that the store had to close as there was no pharmacist available."

The store has now reopened.

A Boots spokesperson responded to Pharmacy Business on Tuesday: "The Boots store in Britannia Centre in Hinckley was temporarily closed yesterday morning for a short time due to pharmacist availability.

"The store reopened in the afternoon and continues to trade as normal.

"We apologise for any inconvenience this caused our customers."

boots ukpharmacy closure; shortage of pharmacists

Related News

NHS app to boost clinical trials
News

Government to use NHS app to boost clinical trials

Over four million flu vaccines across England in the 2024/25 winter flu season.
News

Community pharmacy administered over four million flu vaccines

More For You

Chemotherapy-free leukaemia treatment

The trial found that a combination of two cancer drugs, ibrutinib and venetoclax, could perform better than chemotherapy among patients with chronic lymphocytic leukaemia.

iStock

Chemotherapy-free leukaemia treatment shows promise during trial

In a breakthrough in leukaemia research, scientists in the UK have tested a chemotherapy-free approach, involving a combination of targeted drugs, which may offer better outcomes.

The new treatment could radically change the way chronic lymphocytic leukaemia (CLL), the most common form of leukaemia in adults, is treated.

Keep ReadingShow less
Locum pharmacists in the UK work in a difficult environment, and many are dissatisfied with their jobs.

Locum pharmacists in the UK work in a difficult environment, and many are dissatisfied with their jobs.

iStock

Locums should stand up for their interests, say 'no' to unfair terms: PDA

The Pharmacists' Defence Association (PDA) has advised locum pharmacists to be vigilant about their interests and negotiate directly with their businesses, avoid working with digital platforms driven by algorithms, and be aware of regressive contract terms.

The not-for-profit organisation issued such an advisory following its survey of 1,300 UK locum pharmacists, which showed that they work in a difficult environment and that most are dissatisfied with their jobs.

Keep ReadingShow less
Wales ranked worst for second-trimester abortion access in the UK

Each year about 175 women travel from Wales to England for care

Wales ranked worst for second-trimester abortion access in the UK

A leading healthcare charity has revealed that Wales is the worst part of the United Kingdom for allowing surgical abortions for women.

Surgical abortion is the process removing pregnancy from the womb by inducing local anaesthesia, conscious sedation or general anaesthesia.

Keep ReadingShow less
The fund offers £150 per eligible child - for up to three children per household.

The fund offers £150 per eligible child - for up to three children per household.

Charity reopens funding to ease back to school financial pressures for community pharmacists

Community pharmacists struggling with the costs of their children going back to school can apply for funding from The Leverhulme Trade Charities Trust (LTCT)

The Trust is providing up to £100,000 of support to those working in a community pharmacy or are a registered pharmacist or pharmacy technician

Keep ReadingShow less
Germany's BioNTech to buy CureVac to boost cancer research

Both biotech companies have been working for years in the area of mRNA vaccines and treatments

Germany's BioNTech to buy CureVac to boost cancer research

Germany's BioNTech is buying domestic rival CureVac for $1.25 billion, bringing together two pharmaceutical firms specialised in mRNA technology with the goal of advancing cancer treatments.

BioNTech, which developed the first coronavirus vaccine to be approved in the West along with US pharmaceutical giant Pfizer, said the acquisition would "bring together complementary capabilities and leverage technologies".

Keep ReadingShow less
© Copyright 2025 Garavi Gujarat Publications Ltd & Garavi Gujarat Publications USA Inc